## West of Scotland NEONATAL Parenteral Drug Monographs

## **Cefotaxime IntraVenous**

**FORM** Powder for injection

**INDICATION** 

- a) Treatment of severe infection including meningitis where sensitivities indicate.
- b) Treatment of ophthalmia neonatorum without systemic disease
- c) Treatment of ophthalmia neonatorum with disseminated gonococcal disease

#### **DOSE RANGE**

#### a) TREATMENT OF SEVERE INFECTION INCLUDING MENINGITIS

AGE	DOSE	FREQUENCY	ROUTE
Neonate < 7 days	50mg/kg/dose	Every 12 hours	I.V
Neonate 7 to 21 days	50mg/kg/dose	Every 8 hours	I.V
Neonate > 21 days -	50mg/kg/dose	Every 6 hours	I.V
6months		-	

b) TREATMENT OF OPHTHALMIA NEONATORUM WITHOUT SYSTEMIC DISEASE

AGE	DOSE	FREQUENCY	ROUTE
Neonate	100mg/kg	Single dose	IV

# c) TREATMENT OF OPHTHALMIA NEONATORUM WITH DISSEMINATED GONOCOCCAL DISEASE

AGE	DOSE	FREQUENCY	ROUTE
Neonate	50mg/kg	Every 8 hours	IV

**RECONSTITUTION** Reconstitute a 500mg vial with 4.8ml Water for Injection to give 500mg

in 5ml Solution

**DILUTION** Not required

METHOD OF ADMINISTRATION

May be given by slow IV bolus over 3-5 minutes

**Dosage Guide:** 

500mg in 5ml250mg in 2.5ml25mg in 0.25ml

QEUH Post–Natal wards only
Post Natal Wards – dose banded Cefotaxime

Weight < 3.5kg Cefotaxime 125mg BD Weight ≥ 3.5kg Cefotaxime 175mg BD

Weight <2.25kg or >7kg 50mg/kg BD

Cefotaxime\_IVWOSNeo Page 1 of 2



## West of Scotland NEONATAL Parenteral Drug Monographs

#### **COMPATIBILITY**

Solution compatibility	Sodium Chloride 0.45%, Sodium chloride 0.9%, Glucose 5%, Glucose 10%	
Solution incompatibility	No Information	
IV Line compatibility	Aciclovir, Caffeine citrate, Metronidazole, TPN	
IV Line incompatibility	Aminoglycoside Antibiotic, Doxapram, Heparin, Ranitidine, Sodium	
	Bicarbonate	

# THIS LIST IS NOT EXHAUSTIVE PLEASE CONTACT PHARMACY FOR FURTHER INFORMATION ON COMPATIBILITY WITH ANY MEDICINES NOT INCLUDED

### **CAUTIONS, CONTRA-INDICATIONS AND SIDE EFFECTS**

- See Summary of Product Characteristics and most recent edition of BNF for Children (links below)

#### **FURTHER INFORMATION**

- Variations in the intensity of colour of the freshly prepared solution do not indicate change in potency or safety
- Displacement Volume 0.2ml/500mg
- Extravasation risk
- May cause positive coombs test.
- Cefotaxime may be associated with reversible late-onset Neutropenia and Eosinophillia.

**PH** 4.5 - .6.5

LICENSED STATUS Licensed for use in all ages

LINKS BNF for Children: / Electronic Medicines Compendium

APPLICABLE POLICIES West of Scotland Neonatal Guidelines:

Consult local policy if applicable

Document Number:	006	Supersedes:	005
Prepared by:	WoS Neo Pharm group	Checked by	Peter Mulholland
Date prepared	May 2016	Date updated	February 2020
Updated by	WoS Neonatal Pharmacists	Review Date	February 2023

### Administer reconstituted solutions immediately.

All vials, ampoules and infusion bags are for single use only unless otherwise stated.

Dose may vary depending on indication, age, renal function, hepatic function, and concomitant medications. This monograph should be used in conjunction with the package insert, BNF for Children, and Summary of Product Characteristics. For further advice contact your clinical pharmacist or pharmacy department.

Cefotaxime\_IVWOSNeo Page 2 of 2